Review highlights regulators that modulate Hippo signaling via Yki/YAP1 interactions, indicating their role in cellular outcomes.
In a canonical view of Hippo signaling, the upstream kinases Hippo/MST and Warts (Wts)/large tumor suppressor (LATS) act as an on/off switch that controls phosphorylation and nuclear access of the key pathway effectors, Yorkie (Yki)/Yes-associated protein 1 (YAP1)/transcriptional coactivator with PDZ-binding motif (TAZ). However, studies in flies and mammals have revealed multiple additional regulators that directly associate with Yki/YAP1, often via PPxY motif/WW domain interactions, and fine-tune Hippo pathway activity. In this review, we highlight such "tuners" located at the endosomal membranes, the cell cortex, and in the nucleus, which regulate Yki/YAP1 turnover, nucleocytoplasmic shuttling, and nuclear activity. These factors can set the overall levels of available Yki/YAP1 via sequestration in various subcellular compartments and endosomal/proteasomal degradation. Nuclear "tuners" can direct the Hippo pathway toward specific cellular outcomes, in part through unique transcriptional programs established in concert with Yki/YAP1. Future efforts will be directed at elucidating how the activities of these multiple regulators are coordinated in vivo.
No takes yet. Share an insight, caveat, or question.
Veraksa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: